No Cover Image

Journal article 419 views 76 downloads

Finerenone in the management of diabetes kidney disease

Parijat De, May T Khine, Andrew Frankel, Gabrielle Goldet, Debasish Banerjee, Rosa M Montero, Tahseen A Chowdhury, Damien Fogarty, Janaka Karalliedde, Ritwika Mallik, Dipesh C Patel, Mona Wahba, Peter Winocour, Sagen Zac-Varghese, Steve Bain Orcid Logo, Adnan Sharif, Srikanth Bellary, Indranil Dasgupta

BMC Nephrology, Volume: 26, Issue: 1

Swansea University Author: Steve Bain Orcid Logo

  • 68787.VoR.pdf

    PDF | Version of Record

    © The Author(s) 2025. This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

    Download (1003.66KB)

Check full text

DOI (Published version): 10.1186/s12882-025-03985-9

Abstract

People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular...

Full description

Published in: BMC Nephrology
ISSN: 1471-2369
Published: Springer Science and Business Media LLC 2025
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa68787
first_indexed 2025-02-03T12:54:58Z
last_indexed 2025-03-04T05:37:56Z
id cronfa68787
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2025-03-03T14:54:02.8238823</datestamp><bib-version>v2</bib-version><id>68787</id><entry>2025-02-03</entry><title>Finerenone in the management of diabetes kidney disease</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2025-02-03</date><deptcode>MEDS</deptcode><abstract>People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK.</abstract><type>Journal Article</type><journal>BMC Nephrology</journal><volume>26</volume><journalNumber>1</journalNumber><paginationStart/><paginationEnd/><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>1471-2369</issnElectronic><keywords>Diabetes; Hypertension; Albuminuria; Diabetic kidney disease; Finerenone; ACE inhibitors; Angiotensin receptor blockers; Renin Angiotensin Aldosterone System (RAAS)</keywords><publishedDay>8</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2025</publishedYear><publishedDate>2025-02-08</publishedDate><doi>10.1186/s12882-025-03985-9</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2025-03-03T14:54:02.8238823</lastEdited><Created>2025-02-03T12:47:48.9410079</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Parijat</firstname><surname>De</surname><order>1</order></author><author><firstname>May T</firstname><surname>Khine</surname><order>2</order></author><author><firstname>Andrew</firstname><surname>Frankel</surname><order>3</order></author><author><firstname>Gabrielle</firstname><surname>Goldet</surname><order>4</order></author><author><firstname>Debasish</firstname><surname>Banerjee</surname><order>5</order></author><author><firstname>Rosa M</firstname><surname>Montero</surname><order>6</order></author><author><firstname>Tahseen A</firstname><surname>Chowdhury</surname><order>7</order></author><author><firstname>Damien</firstname><surname>Fogarty</surname><order>8</order></author><author><firstname>Janaka</firstname><surname>Karalliedde</surname><order>9</order></author><author><firstname>Ritwika</firstname><surname>Mallik</surname><order>10</order></author><author><firstname>Dipesh C</firstname><surname>Patel</surname><order>11</order></author><author><firstname>Mona</firstname><surname>Wahba</surname><order>12</order></author><author><firstname>Peter</firstname><surname>Winocour</surname><order>13</order></author><author><firstname>Sagen</firstname><surname>Zac-Varghese</surname><order>14</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>15</order></author><author><firstname>Adnan</firstname><surname>Sharif</surname><order>16</order></author><author><firstname>Srikanth</firstname><surname>Bellary</surname><order>17</order></author><author><firstname>Indranil</firstname><surname>Dasgupta</surname><order>18</order></author></authors><documents><document><filename>68787__33728__2627192913824593b51c943613cef709.pdf</filename><originalFilename>68787.VoR.pdf</originalFilename><uploaded>2025-03-03T14:48:21.7679821</uploaded><type>Output</type><contentLength>1027750</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; The Author(s) 2025. This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2025-03-03T14:54:02.8238823 v2 68787 2025-02-03 Finerenone in the management of diabetes kidney disease 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2025-02-03 MEDS People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK. Journal Article BMC Nephrology 26 1 Springer Science and Business Media LLC 1471-2369 Diabetes; Hypertension; Albuminuria; Diabetic kidney disease; Finerenone; ACE inhibitors; Angiotensin receptor blockers; Renin Angiotensin Aldosterone System (RAAS) 8 2 2025 2025-02-08 10.1186/s12882-025-03985-9 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University 2025-03-03T14:54:02.8238823 2025-02-03T12:47:48.9410079 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Parijat De 1 May T Khine 2 Andrew Frankel 3 Gabrielle Goldet 4 Debasish Banerjee 5 Rosa M Montero 6 Tahseen A Chowdhury 7 Damien Fogarty 8 Janaka Karalliedde 9 Ritwika Mallik 10 Dipesh C Patel 11 Mona Wahba 12 Peter Winocour 13 Sagen Zac-Varghese 14 Steve Bain 0000-0001-8519-4964 15 Adnan Sharif 16 Srikanth Bellary 17 Indranil Dasgupta 18 68787__33728__2627192913824593b51c943613cef709.pdf 68787.VoR.pdf 2025-03-03T14:48:21.7679821 Output 1027750 application/pdf Version of Record true © The Author(s) 2025. This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. true eng http://creativecommons.org/licenses/by-nc-nd/4.0/
title Finerenone in the management of diabetes kidney disease
spellingShingle Finerenone in the management of diabetes kidney disease
Steve Bain
title_short Finerenone in the management of diabetes kidney disease
title_full Finerenone in the management of diabetes kidney disease
title_fullStr Finerenone in the management of diabetes kidney disease
title_full_unstemmed Finerenone in the management of diabetes kidney disease
title_sort Finerenone in the management of diabetes kidney disease
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Parijat De
May T Khine
Andrew Frankel
Gabrielle Goldet
Debasish Banerjee
Rosa M Montero
Tahseen A Chowdhury
Damien Fogarty
Janaka Karalliedde
Ritwika Mallik
Dipesh C Patel
Mona Wahba
Peter Winocour
Sagen Zac-Varghese
Steve Bain
Adnan Sharif
Srikanth Bellary
Indranil Dasgupta
format Journal article
container_title BMC Nephrology
container_volume 26
container_issue 1
publishDate 2025
institution Swansea University
issn 1471-2369
doi_str_mv 10.1186/s12882-025-03985-9
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 1
active_str 0
description People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK.
published_date 2025-02-08T05:26:25Z
_version_ 1851097754344882176
score 11.089386

Similar Items